June 26, 2002

Osteopontin as a Biomarker for Ovarian Cancer

Author Affiliations

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor


Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002

JAMA. 2002;287(24):3208-3210. doi:10.1001/jama.287.24.3206

To the Editor: In their study, Dr Kim and colleagues1 frequently combined ovarian carcinomas with ovarian "borderline tumors." This grouping is not valid. Although pathologists disagree on terminology for "borderline tumors," they agree on the behavior of this heterogeneous group. The vast majority (about 90%) of serous borderline tumors (the most common type) are benign with virtually 100% survival.2 The aggressive serous borderline tumors have a micropapillary pattern and/or invasive peritoneal implants, and patients with these tumors have a 7-year survival of 60% to 70%.2 Mucinous borderline tumors comprise nearly all the remaining borderline tumors, and aggressive mucinous borderline tumors, previously thought to be ovarian, are now acknowledged to be of gastrointestinal origin.2 The remaining ovarian mucinous borderline tumors are virtually always confined to the ovaries and patients have 100% survival.2 Thus, the grouping of borderline tumors with carcinomas intermixes benign with malignant tumors and renders the results uninterpretable.

First Page Preview View Large
First page PDF preview
First page PDF preview